$ 141.62
Key Takeaways
Risk factor
Strong trading liquidity
Profitability factor
Strong margins and returns
About
Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an etanercept biosimilar referencing ENBREL; ADUHELM for the treatment of Alzheimer's disease;...
Company Valuation
Based on key historical and expected multiples, the stock is undervalued relative to its peers. Specifically, the stock is 'cheap' on P/E, neutral on EV/EBITDA, reasonabl
Target Price
The average target price of BIIB is 173 and suggests 22% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to increas
